Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cureus ; 14(7): e26881, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35978760

RESUMO

Although significant advances in the treatment of prostate cancer (PC) have recently been made, the treatment of metastatic liver disease remains challenging. Recent advances have led to multiple novel therapies and multi-treatment approaches combining systemic and locoregional modalities, such as thermal ablation, representing a promising strategy that has received attention in recent years. Nevertheless, no standard locoregional treatment regimens exist for the management of liver metastases of PC. In addition, regional therapy alone is unlikely to provide durable cancer control. Here, we report for the first time a successful treatment of hepatic metastases of PC using stereotactic image-guided percutaneous microwave ablation and the poly (ADP-ribose) polymerase-1 inhibitor, olaparib.

2.
Am J Health Syst Pharm ; 79(15): 1296-1300, 2022 07 22.
Artigo em Inglês | MEDLINE | ID: mdl-35451022

RESUMO

PURPOSE: The aim of this review was to build upon previous literature describing the maximum duration for which refrigerated medications can tolerate room temperature excursions while maintaining stability and potency. METHODS: During a 12-month period ending in June 2021, the prescribing information and published monographs from multiple pharmacy compendia were reviewed for all medications and biologic products approved by the US Food and Drug Administration (FDA) for human use since January 2000. Products that were subsequently withdrawn from the US market were excluded. When temperature excursion data was unavailable in published form, product manufacturers were surveyed via telephone and/or email. Acceptable storage information for all products for which storage is recommended at temperatures below room temperature (20-25 °C [68-77 °F]) was compiled and arranged in tabular format. RESULTS: Of the 705 products or formulations approved by FDA during the predefined time period, 246 were identified as requiring storage at temperatures below room temperature. After review of available prescribing information and manufacturer communications, if applicable, acceptable periods of excursion to temperatures at room temperature or higher were identified for 214 products (87%). CONCLUSION: Information related to acceptable periods of room temperature excursion was compiled for a total of 214 products approved for US distribution since 2000. The included tables may increase patient safety and decrease medication loss or related expenditures.


Assuntos
Assistência Farmacêutica , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Humanos , Preparações Farmacêuticas , Temperatura , Estados Unidos , United States Food and Drug Administration
3.
BMJ Case Rep ; 14(2)2021 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-33637494

RESUMO

Recessive dystrophic epidermolysis bullosa (RDEB) is a multisystem inherited disorder associated with fragile skin, blister formation and poor wound healing. Patients with RDEB are at significantly increased risk of recurrent and aggressive cutaneous squamous cell carcinoma (cSCC) and because of their disease complexity, conventional therapies may not be possible. Recent advances in cancer immunotherapy have led to the successful use of immune checkpoint inhibitors (ICIs) in melanoma and other malignancies. However, the effects of ICIs in patients with cSCC and RDEB are currently unknown. A 30-year-old woman with RDEB and multiple unresectable cSCCs was found to have high tumour mutational burden and PD-L1 (programmed cell death-ligand 1) expression. She was started on an ICI, which yielded disease control and was well tolerated. Furthermore, her RDEB wounds improved. This case demonstrates successful use of immunotherapy for advanced cSCC in RDEB, a disease that is often challenging to treat with local therapies.


Assuntos
Carcinoma de Células Escamosas , Epidermólise Bolhosa Distrófica , Neoplasias Cutâneas , Adulto , Carcinoma de Células Escamosas/terapia , Epidermólise Bolhosa Distrófica/complicações , Epidermólise Bolhosa Distrófica/terapia , Feminino , Humanos , Fatores Imunológicos , Imunoterapia , Neoplasias Cutâneas/terapia
4.
Nanomedicine ; 13(3): 955-963, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27884637

RESUMO

This study represents a novel phototheranostic nanoplatform based on the near-infrared (NIR) heptamethine cyanine dye, IR775, which is capable of concurrent real-time fluorescence imaging and cancer eradication with combinatorial phototherapy. To achieve water solubility and enhance tumor delivery, the hydrophobic IR775 dye was loaded into a biocompatible polymeric nanoparticle with a diameter of ~40nm and slightly negative surface charge (-2.34mV). The nanoparticle-encapsulated hydrophobic IR775 dye (IR775-NP) is characterized by an enhanced fluorescence quantum yield (16%) when compared to the water soluble analogs such as ICG (2.7%) and IR783 (8%). Furthermore, the developed IR-775-NP efficiently generates both heat and reactive oxygen species under NIR light irradiation, eradicating cancer cells in vitro. Finally, animal studies revealed that the IR775-NP accumulates in cancer tumors after systemic administration, efficiently delineates them with NIR fluorescence signal and completely eradicates chemo resistant cancer tissue after a single dose of combinatorial phototherapy.


Assuntos
Corantes Fluorescentes/farmacocinética , Corantes Fluorescentes/uso terapêutico , Indóis/farmacocinética , Indóis/uso terapêutico , Neoplasias Ovarianas/terapia , Fototerapia/métodos , Nanomedicina Teranóstica/métodos , Animais , Carbocianinas/farmacocinética , Carbocianinas/uso terapêutico , Linhagem Celular Tumoral , Feminino , Corantes Fluorescentes/administração & dosagem , Corantes Fluorescentes/análise , Humanos , Indóis/administração & dosagem , Indóis/análise , Camundongos , Nanopartículas/administração & dosagem , Nanopartículas/análise , Imagem Óptica/métodos , Neoplasias Ovarianas/diagnóstico por imagem , Ovário/diagnóstico por imagem
5.
Nanoscale ; 7(9): 3888-902, 2015 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-25422147

RESUMO

Multifunctional theranostic platforms capable of concurrent near-infrared (NIR) fluorescence imaging and phototherapies are strongly desired for cancer diagnosis and treatment. However, the integration of separate imaging and therapeutic components into nanocarriers results in complex theranostic systems with limited translational potential. A single agent-based theranostic nanoplatform, therefore, was developed for concurrent NIR fluorescence imaging and combinatorial phototherapy with dual photodynamic (PDT) and photothermal (PTT) therapeutic mechanisms. The transformation of a substituted silicon naphthalocyanine (SiNc) into a biocompatible nanoplatform (SiNc-NP) was achieved by SiNc encapsulation into the hydrophobic interior of a generation 5 polypropylenimine dendrimer following surface modification with polyethylene glycol. Encapsulation provides aqueous solubility to SiNc and preserves its NIR fluorescence, PDT and PTT properties. Moreover, an impressive photostability in the dendrimer-encapsulated SiNc has been detected. Under NIR irradiation (785 nm, 1.3 W cm(-2)), SiNc-NP manifested robust heat generation capability (ΔT = 40 °C) and efficiently produced reactive oxygen species essential for PTT and PDT, respectively, without releasing SiNc from the nanopaltform. By varying the laser power density from 0.3 W cm(-2) to 1.3 W cm(-2) the therapeutic mechanism of SiNc-NP could be switched from PDT to combinatorial PDT-PTT treatment. In vitro and in vivo studies confirmed that phototherapy mediated by SiNc can efficiently destroy chemotherapy resistant ovarian cancer cells. Remarkably, solid tumors treated with a single dose of SiNc-NP combined with NIR irradiation were completely eradicated without cancer recurrence. Finally, the efficiency of SiNc-NP as an NIR imaging agent was confirmed by recording the strong fluorescence signal in the tumor, which was not photobleached during the phototherapeutic procedure.


Assuntos
Dendrímeros/química , Nanopartículas/química , Compostos de Organossilício/química , Neoplasias Ovarianas/terapia , Fármacos Fotossensibilizantes/química , Porfirinas/química , Animais , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Feminino , Humanos , Raios Infravermelhos , Camundongos , Camundongos Nus , Compostos de Organossilício/farmacologia , Neoplasias Ovarianas/diagnóstico , Fotoquimioterapia , Fármacos Fotossensibilizantes/farmacologia , Fototerapia , Polipropilenos/química , Porfirinas/farmacologia , Oxigênio Singlete/metabolismo , Espectroscopia de Luz Próxima ao Infravermelho , Nanomedicina Teranóstica
6.
J Virol ; 76(18): 9345-54, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12186917

RESUMO

Hepatitis C virus (HCV) is remarkably efficient in establishing persistent infection, possibly mediated by an impaired immune response to HCV infection. There is compelling evidence that HCV can infect immune cells, such as macrophages, B cells, and T cells. It has been previously reported that HCV core, the first protein expressed during the early phase of viral infection, contains the immunomodulatory function of suppressing host immune responses. This altered function of immune cells caused by HCV infection may explain the ineffective immune response to HCV. To further characterize the immunomodulatory role of HCV core in vivo, we generated transgenic (TG) mice by directing the expression of core protein to T lymphocytes by using the CD2 promoter. T-lymphocyte responses, including the production of gamma interferon and interleukin-2, were significantly diminished in these mice compared to their non-TG littermates. The inhibition of T-lymphocyte responsiveness may be due to the increased susceptibility of peripheral T lymphocytes to Fas-mediated apoptosis. Surprisingly, significant lymphocyte infiltration was observed in the portal tracts of livers isolated from core TG mice, associated with increasing serum alanine aminotransferase levels. Moreover, no intrahepatic lymphocytes or liver damage was found in non-TG littermates and core TG mice bred to Fas-deficient lpr mice. These results suggest that HCV core drives liver injury by increasing Fas-mediated apoptosis and liver infiltration of peripheral T cells.


Assuntos
Hepacivirus/patogenicidade , Hepatite C/imunologia , Hepatite C/fisiopatologia , Tolerância Imunológica , Fígado/patologia , Proteínas do Core Viral/imunologia , Proteínas do Core Viral/metabolismo , Animais , Apoptose , Modelos Animais de Doenças , Hepatite C/patologia , Humanos , Imuno-Histoquímica , Fígado/metabolismo , Ativação Linfocitária , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos CBA , Camundongos Transgênicos , Linfócitos T/imunologia , Receptor fas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...